181 related articles for article (PubMed ID: 32291233)
41. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
42. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
43. Performance of CT Compared with
Mokrane FZ; Chen A; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Duléry R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Houot R; Dercle L
Radiology; 2020 Jun; 295(3):651-661. PubMed ID: 32286191
[TBL] [Abstract][Full Text] [Related]
44. Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.
Baues C; Goergen H; Fuchs M; Rosenbrock J; Celik E; Eich H; Kobe C; Voltin CA; Engert A; Borchmann P; Marnitz S
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):900-906. PubMed ID: 34389407
[TBL] [Abstract][Full Text] [Related]
45. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.
Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A
Ann Oncol; 2017 Dec; 28(12):3051-3057. PubMed ID: 28950332
[TBL] [Abstract][Full Text] [Related]
46. Retrospective single-center experience with OEPA/COPDAC and PET-CT based strategy for pediatric Hodgkin lymphoma in a LMIC setting.
Palayullakandi A; Trehan A; Jain R; Kumar R; Mittal BR; Kapoor R; Srinivasan R; Kakkar N; Bansal D
Pediatr Hematol Oncol; 2022 Oct; 39(7):587-599. PubMed ID: 35271413
[TBL] [Abstract][Full Text] [Related]
47. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.
Bakhshi S; Bhethanabhotla S; Kumar R; Agarwal K; Sharma P; Thulkar S; Malhotra A; Dhawan D; Vishnubhatla S
J Nucl Med; 2017 Apr; 58(4):577-583. PubMed ID: 27754902
[TBL] [Abstract][Full Text] [Related]
48. Positron Emission Tomography Scanning in the Management of Hodgkin Lymphoma Patients: A Single-Institution Experience.
Zabrocka E; Sierko E; Wojtukiewicz MZ
Adv Clin Exp Med; 2016; 25(6):1185-1192. PubMed ID: 28028972
[TBL] [Abstract][Full Text] [Related]
49. Combined modality treatment: Outcome in patients with Hodgkin's lymphoma.
Yadav BS; Sharma SC; Malhotra P; Prakash G
J Cancer Res Ther; 2020; 16(1):1-6. PubMed ID: 32362601
[TBL] [Abstract][Full Text] [Related]
50. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
51. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
52. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission.
Pingali SR; Jewell SW; Havlat L; Bast MA; Thompson JR; Eastwood DC; Bartlett NL; Armitage JO; Wagner-Johnston ND; Vose JM; Fenske TS
Cancer; 2014 Jul; 120(14):2122-9. PubMed ID: 24711253
[TBL] [Abstract][Full Text] [Related]
53. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
Pavlovsky A; Fernandez I; Kurgansky N; Prates V; Zoppegno L; Negri P; Milone G; Cerutti I; Zabaljauregui S; Mariano R; Grecco HF; Basquiera AL; Saba S; Rudoy S; Sackmann F; Castano V; Remaggi G; Cabrejo M; Roveri E; Casale MF; Cabane V; Taus R; Venturini C; Sakamoto F; Varela AI; Riddick M; Pavlovsky S;
Br J Haematol; 2019 Jun; 185(5):865-873. PubMed ID: 30864146
[TBL] [Abstract][Full Text] [Related]
54. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
[TBL] [Abstract][Full Text] [Related]
55. [Response to ABVD chemotherapeutic protocol in patients with early stage Hodgkins lymphoma].
Díaz J; Soto K; Ernst D
Rev Med Chil; 2017 May; 145(5):619-622. PubMed ID: 28898338
[TBL] [Abstract][Full Text] [Related]
56. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
[TBL] [Abstract][Full Text] [Related]
57. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Sibon D; Bonnet C; Berriolo-Riedinger A; Edeline V; Parrens M; Damotte D; Coso D; André M; Meignan M; Rossi C
J Clin Oncol; 2022 Apr; 40(10):1091-1101. PubMed ID: 34990281
[TBL] [Abstract][Full Text] [Related]
58. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.
Truong Q; Shah N; Knestrick M; Curley B; Hu Y; Craig M; Hamadani M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):50-5. PubMed ID: 24119465
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
[TBL] [Abstract][Full Text] [Related]
60. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma.
Park SI; Shea TC; Olajide O; Reddy NM; Budde LE; Ghosh N; Deal AM; Noe JF; Ansell SM
Blood Adv; 2020 Jun; 4(11):2548-2555. PubMed ID: 32516414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
